Anticancer Therapeutic Radiopharmaceuticals Currently Approved by Regulators in United States
| Agent | Trade name | Year of FDA approval | Primary endpoint | Indication |
|---|---|---|---|---|
| 89Sr-chloride | Metastron (GE Healthcare) | 1993 | Pain/analgesics | Painful skeletal metastases |
| 153Sm-lexidronam | Quadramet (Dow Chemical Co.) | 1997 | Pain/analgesics | Painful osteoblastic metastases |
| 90Y-ibritumomab tiuxetan | Zevalin (Acrotech Biopharma) | 2002 | Tumor response rate | Low-grade or follicular lymphoma |
| 131I-tositumomab | Bexxar (GlaxoSmithKline) | 2003 | Tumor response rate | Low-grade or follicular lymphoma |
| 223Ra-dichloride | Xofigo (Bayer) | 2013 | OS | mCRPC |
| 177Lu-DOTATATE | Lutathera (Advanced Accelerator Applications) | 2018 | Progression-free survival | Select neuroendocrine tumors |
| 131I-iobenguane | Azedra (Progenics Pharmaceuticals) | 2018 | Lower blood pressure and tumor response rate | Select pheochromocytoma or paraganglioma |
| 177Lu-PSMA-617 | Pluvictoa (Advanced Accelerator Applications) | 2022 | OS and rPFS | PSMA PET-positive mCRPC after ARPI and taxane |
PSMA = prostate-specific membrane antigen.